Emerald Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 17-12-2024
- Paid Up Capital ₹ 0.20 M
as on 17-12-2024
- Company Age 22 Year, 2 Days
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.60 M
as on 17-12-2024
- Revenue %
(FY 2020)
- Profit 4136.11%
(FY 2020)
- Ebitda 120.55%
(FY 2020)
- Net Worth 3.92%
(FY 2020)
- Total Assets 15.08%
(FY 2020)
About Emerald Pharma
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M.
The company has closed loans amounting to ₹1.60 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sanjay Prajapati and Govind Prajapati serve as directors at the Company.
- CIN/LLPIN
U24232MP2002PTC015456
- Company No.
015456
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Dec 2002
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Raipur, Chattisgarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Emerald Pharma Private Limited offer?
Emerald Pharma Private Limited offers a wide range of products and services, including Multivitamin Syrup & Drops, Iron Folic Acid Syrup, Herbal Oil, Vitamin Tablets & Capsules, Folic Acid Tablet.
Who are the key members and board of directors at Emerald Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Prajapati  | Director | 24-Feb-2006 | Current |
| Govind Prajapati | Director | 19-Dec-2002 | Current |
Financial Performance of Emerald Pharma.
Emerald Pharma Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 4136.11% increase in profit. The company's net worth moved up by a moderate rise of 3.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Emerald Pharma?
In 2017, Emerald Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 18 Dec 2009 | ₹1.50 M | Satisfied |
State Bank Of Indore Creation Date: 13 Feb 2004 | ₹0.10 M | Satisfied |
How Many Employees Work at Emerald Pharma?
Unlock and access historical data on people associated with Emerald Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Emerald Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Emerald Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
